Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The ACR’s State-of-the-Art Clinical Symposium: Rheumatic, Malignant Disease Mimics Call for Diligence from Rheumatologists

Thomas R. Collins  |  Issue: July 2015  |  July 14, 2015

In treating patients who develop elevated CK levels, Dr. Mammen will generally continue statin use unless the CK gets to be triple baseline levels or they become weak—in which case, he’ll discontinue use and see if they improve. If they don’t, he’ll look for another type of myopathy.

He emphasized the continued benefit of statins despite these potential problems.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Statins, despite everything I just spent the last half-hour telling you, are really great medications, and for most of our patients, the benefits of these medications far outweigh the risks,” Dr. Mammen said.

Viral Infections with Rheumatic Manifestations

Dr. Jonas

Dr. Jonas

Beth Jonas, MD, associate professor of medicine at the University of North Carolina School of Medicine’s Thurston Arthritis Research Center, reviewed viral infections that may present with rheumatic symptoms.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Hepatitis A, B and C infections can bring about these symptoms, but rheumatologists in the U.S. are most likely to see chronic hepatitis C (HCV) patients. Chronic HCV infection is associated with cryoglobulinemic vasculitis, arthritis and, sometimes, polyarteritis nodosa. The arthritis associated with HCV is usually non-erosive, but the disease can be difficult to distinguish from RA because many patients are RF positive, although a negative CCP antibody can help. HCV arthritis is more often seen in women, in older patients and in patients with more advanced fibrosis of the liver.

Physicians need to know that RA and HCV can coexist.

Patients treated with interferon for HCV can see their RA worsen, Dr. Jonas cautioned.

“I’ve seen patients who were diagnosed with HCV and thought to have HCV-related arthritis. Treatment with interferon led to a complete virologic response, but the arthritis persisted. In retrospect, the arthritis was likely RA.”

She also warned clinicians to be on the lookout for patients infected with the Chikungunya virus, which was first seen in Africa but has now spread to the Americas. Hundreds of cases have been seen in the U.S., mostly in Florida and New York in patients who have returned from the Caribbean.

Symptoms include fever, arthralgia and arthritis, and myalgia that can render some patients bedridden. In most patients, the fever and rash resolve in one to two weeks, but the arthritis can persist past six weeks or even much longer.

A 2012 study from India after an outbreak there found that arthritis or arthralgia lasted more than six weeks in 315 of 509 patients, and 5% had arthritis more than two years later.4

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsMeeting Reports Tagged with:AC&Rclinical symposiumDiagnosisDiseasemalignantmimicspatient carerheumaticrheumatologistTreatment

Related Articles

    Meet the HEP C Challenge

    December 1, 2008

    Keep a hepatitis C virus infection from hindering RA treatment

    Drug Updates

    January 1, 2009

    Information on safety, labeling changes, and pharmaceutical research

    Fellows’ Forum Case Report: Necrotizing Autoimmune Myopathy

    December 18, 2017

    Necrotizing autoimmune myopathy (NAM) is a relatively recently discovered subgroup of inflammatory myopathies. NAM is characterized by predominant muscle fiber necrosis and regeneration with little or no inflammation.1 One subgroup of NAM is 3-hydroxy-3-methylglutaryl-CoA reductase antibody (HMGCR Ab)-related immune-mediated necrotizing myopathy (IMNM), which occurs (rarely) after statin exposure, with a rough incidence of two per…

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences